promo_leaderboard Ad
‹ All stocks
CYTK

Cytokinetics, Incorporated

CYTK · NASDAQ · Healthcare
$52.42
▼ $0.75 (-1.42%)
$52.42 $56.38 $60.35 $64.32 $52.42 Oct 18 Nov 02 Nov 17
Day range
$51.87 – $52.90
Year range
$51.87 – $88.31
Open
$52.74
Previous close
$53.17
Market cap
$7.30B
Volume (24h)
$102.9K
Volume (52w)
$5.40M
Performance
7D
▼ -6.70%
1M
▼ -16.34%
3M
▼ -32.58%
6M
▼ -32.85%
1Y
▼ -21.71%
YTD
▼ -15.09%
3Y
▲ 62.23%
5Y
▲ 28.69%
All-time
▼ -46.27%
Key statistics
P/E ratio
-8.68
EPS (TTM)
$-6.04
Dividend yield
—
Dividend (TTM)
—
Payout ratio
—
Shares outstanding
139.3M
About Cytokinetics, Incorporated

Cytokinetics, Incorporated is an advanced biopharmaceutical company dedicated to the research, development, and commercialization of therapies that modulate muscle function. These novel compounds aim to address debilitating diseases. The core of their pipeline consists of small molecule drug candidates specifically designed to influence muscle performance and contraction at a fundamental level. Currently, several key programs are in late-stage clinical trials: Omecamtiv mecarbil, a cardiac myosin activator, is being evaluated in Phase III for heart failure patients. Reldesemtiv, which targets skeletal muscle troponin activation, is in Phase III development for amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). Aficamten, a cardiac myosin inhibitor, has reached Phase III for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Earlier-stage assets include CK-136, a cardiac troponin activator, and CK-3772271, another cardiac myosin inhibitor, both currently undergoing Phase I clinical assessment. The company also maintains a strategic collaboration with Astellas Pharma Inc. Established in 1997, Cytokinetics is headquartered in South San Francisco, California.

Visit website
Country: United States of America
More in Healthcare